Trial Profile
A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancers
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Leflunomide (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jun 2023 Planned End Date changed from 1 Oct 2025 to 1 Oct 2026.
- 20 Jun 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2025.
- 11 Nov 2021 Planned End Date changed from 20 Oct 2021 to 1 Oct 2025.